ZBH · 8-K · 20260805PR335108

Capital Return Program

ZIMMER BIOMET HOLDINGS, INC. · 2026-08-05 · Importance 58 · Surprise 42 · In source text

Zimmer Biomet repurchased $487.0 million of common stock in 2025 under its $2.0 billion May 2024 authorization. The repurchases were intended to return cash to investors and offset dilution from share-based compensation. The May 2024 program had $770.2 million remaining at December 31, 2025, before being terminated. On February 9, 2026, the Board authorized a new $1.5 billion program with no expiration date, and the company declared quarterly cash dividends of $0.24 per share during February, May, August and December 2025.

Key facts

• On February 9, 2026 the Board authorized a $1.5 billion share repurchase program effective February 9, 2026 and terminated the existing May 2024 program. source
• In May 2024 the Board authorized a $2.0 billion share repurchase program effective May 29, 2024 with no expiration; in 2025 the company repurchased $487.0 million under this program and $770.2 million remained authorized as of December 31, 2025. source
• Cash flows provided by financing activities were $326.0 million in 2025 compared to cash flows used in financing activities of $484.5 million in 2024. source
• Zim repurchased 1.9 million shares in the three-month period ended March 31, 2023 to minimize dilution from Embody issuance. source
• In February, May, August and December 2025 the Board declared cash dividends of $0.24 per share. source
• Company is authorized to issue 250.0 million shares of preferred stock, none of which were issued or outstanding as of December 31, 2025. source

Impact estimates